Longitude Capital

Longitude Capital’s founders have been investing together since 2002 Our team has over 150 years of combined investing experience in the life sciences industry and has collaborated on over 70 new investments and 150 follow-on investments in the biotechnology, medical technology, and health solutions sectors We operate from our offices in Menlo Park, California, Greenwich, Connecticut and Boston, Massachusetts

Ms Bakker is a Managing Director and Founder of Longitude Capital Prior to Longitude Capital, Ms Bakker was a Managing Director of Pequot Ventures, where she founded the life sciences investment practice Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International, and was a sell-side equity analyst with Banque Paribas Ms Bakker began her career as an investment banker in the corporate finance department at PaineWebber She currently serves on the boards of Ceribell, Endogenex, Nalu, and RxSight (RXST) Selected prior board memberships include Ablation Frontiers (acquired by Medtronic), Alphaeon, AqueSys (acquired by Allergan), Axonics Modulation Technologies (AXNX), CryoVascular Systems (acquired by Boston Scientific), Eargo (EAR), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C R Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), Sadra Medical (acquired by Boston Scientific), and Venus Concept (VERO) Ms Bakker holds an MPA from the Harvard Kennedy School and a BSc from the College of Agriculture and Life Sciences (”CALS”) at Cornell University, where she is a member of the CALS Advisory Council —Focus Areas: Medical Technology, Health Solutions Location: Greenwich Mr Diaz is a Venture Partner of Longitude Capital Concurrently, Mr Diaz serves on the boards of Lexeo Therapeutics, Inozyme (INZY), and is the part-time Chief Business Officer of Opna-IO, a Longitude Capital portfolio company In addition, he consults for various companies in the healthcare industry, including Auven Therapeutics, where he previously served as Managing Director from 2008 to 2018 Prior to joining Auven Therapeutics, he was a Managing Member and co-founder of Diaz & Altschul Capital Management (D&A Capital) Prior to founding D&A Capital, Mr Diaz was a Managing Director and Head of the Healthcare group at Schroder Wertheim & Co Mr Diaz started his career at PaineWebber, where he was a key member of the PaineWebber Healthcare Investment Banking Group and President of PaineWebber Development Corporation Mr Diaz holds an MBA from Harvard Business School and a BA from Harvard University —Focus Areas: Biotechnology (including royalty transactions)Location: Greenwich Mr Enright is a Managing Director and Founder of Longitude Capital Prior to Longitude Capital, Mr Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management Mr Enright began his investment career at PaineWebber Development Corporation Mr Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Boehringer Mannheim (acquired by Roche), and Sandoz (now known as Novartis) Mr Enright currently serves on the boards of Aptinyx (APTX), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Orbus Therapeutics, Rivus Pharmaceuticals, Vera Therapeutics (VERA), as well as the National Venture Capital Association (NVCA) Selected prior board memberships include Aimmune (AIMT, acquired by Nestlé Health Science), Codexis (CDXS), Corcept Therapeutics (CORT), Dascena, Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP), InfaCare Pharmaceutical (acquired by Mallinckrodt), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sequenom (SQNM, acquired by LabCorp), Threshold Pharmaceuticals (THLD), and Vaxcyte (PCVX) Mr Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University —Focus Areas: Biotechnology, Health SolutionsLocation: Menlo Park Mr Galletti is a Managing Director and Founder of Longitude Capital Prior to Longitude Capital, Mr Galletti was a Senior Vice President of Pequot Ventures, where he worked in the life sciences practice Prior to Pequot Ventures, Mr Galletti worked at Amerindo Investment Advisors, Vector Fund Management, and the Global Healthcare Investment Banking Group at J P Morgan & Co Mr Galletti began his career in the life sciences industry at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals Mr Galletti currently serves on the board of Murj Selected prior board memberships include Amphora Medical (acquired), Aptus Endosystems (acquired by Medtronic), and Twelve (acquired by Medtronic), and he has also been involved with prior investments in Ablation Frontiers (acquired by Medtronic), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sadra Medical (acquired by Boston Scientific), and Threshold Pharmaceuticals (THLD) Mr Galletti sits or has sat on advisory boards for the Innovation and New Ventures Office at Northwestern University and the Life Sciences Advisory Board of Silicon Valley Bank Mr Galletti holds an MBA in Finance and Health Services Management from the Kellogg School of Management at Northwestern University and an AB from Princeton University — Focus Areas: Medical Technology, Health Solutions Location: Menlo Park Dr Grunberg is a Managing Director at Longitude Capital Prior to joining Longitude Capital in 2012, Dr Grunberg was a Principal at Rho Ventures and an Engagement Manager at McKinsey & Company Dr Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York-Presbyterian Hospital He has maintained a limited clinical practice in Internal Medicine, including current and previous affiliations with UCSF, Kaiser Permanente, Cornell, and Montefiore Dr Grunberg currently serves on the boards of 89bio (ETNB), On Belay, Somatus, Sydnexis, and WelbeHealth He is also a board observer at Cohere Health and Cortica He previously served on the board of California Cryobank (acquired by GI Partners and now known as Generate Life Sciences) and Kala Pharmaceuticals (KALA) and led Longitude’s investment in Practice Fusion (acquired by Allscripts) While at Rho Ventures, he served on the board of AqueSys (acquired by Allergan) and was a board observer at both SARCode Bioscience (acquired by Shire) and PHT (acquired by ERT) Dr Grunberg holds an MD and an MBA from Duke University, where he was a Fuqua Scholar, and an BA in Economics and English from Amherst College — Focus Areas: Health Solutions, Medical Technology, Biotechnology Location: Menlo Park Managing Director and Chief Financial Officer Ms Helms is a Managing Director and the Chief Financial Officer at Longitude Capital Ms Helms is responsible for the financial reporting of the Firm’s investment funds, as well as the day-to-day management of Firm-wide finance, tax, and accounting matters In addition, Ms Helms supports the Firm’s regulatory compliance program and works closely on legal, investor relations, and operational matters Ms Helms served as the Firm’s Chief Compliance Officer from 2014 to September 2021 Prior to joining Longitude Capital in 2008, Ms Helms was the Controller at Sierra Ventures, a venture capital firm focused on technology, where she managed the finance staff and was responsible for all aspects of financial accounting, reporting, and tax Prior to Sierra Ventures, Ms Helms was an Accounting Manager at NetManage, a publicly-traded software company, and was a Senior Auditor with Arthur Andersen LLP Ms Helms is a licensed CPA (inactive) and graduated cum laude with a BS in Business Administration (Accounting) from San Jose State University —Focus Areas: Finance, Operations, Compliance Location: Menlo Park Dr Hirsch is a Venture Partner and Founder of Longitude Capital Concurrently, Dr Hirsch serves as the CEO of Alpha-9 Dr Hirsch also serves on the boards of Molecular Templates (MTEM), Rapid Micro Biosystems (RPID), Tricida (TCDA) Selected prior board memberships include Amunix Pharmaceuticals (acquired by Sanofi), Civitas Therapeutics (acquired by Acorda), Collegium Pharmaceutical (COLL), Inflazome (acquired by Roche), Poseida Therapeutics (PSTX), and Zavante Therapeutics (acquired by Nabriva (NBVA)) Dr Hirsch also led Longitude Capital’s investments in Amarin (AMRN) and Cadence Pharmaceuticals (CADX, acquired by Mallinckrodt) Prior to Longitude Capital, Dr Hirsch was a Vice President of Pequot Ventures, where he worked in the life sciences practice Prior to Pequot Ventures, Dr Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company Dr Hirsch holds a PhD in Biology from the Massachusetts Institute of Technology, an MD from Harvard Medical School, and a BA in Biology from The Johns Hopkins University — Focus Areas: Biotechnology Location: Boston Mr Wert is a Managing Director at Longitude Capital Mr Wert was previously with Longitude Capital from 2008 to 2012 and rejoined in 2016 Before that, he was a Vice President at Warburg Pincus, where he focused on healthcare investments Prior to joining Longitude Capital, Mr Wert worked in the Global Healthcare Investment Banking Group at Merrill Lynch Mr Wert currently serves on the board of Cortica and is a board observer at Murj, On Belay, Somatus, and WelbeHealth He previously served as a board observer at California Cryobank (acquired by GI Partners and now known as Generate Life Sciences) and was also actively involved in Longitude Capital’s investment in Cohere Health While at Warburg Pincus, Mr Wert served as a board observer at Silk Road Medical (SILK), Outset Medical (OM), and Accriva Diagnostics (acquired by Werfen) Mr Wert holds an MBA from Stanford Graduate School of Business, where he was an Arbuckle Leadership Fellow and received a Certificate in Social Innovation and Public Management He received his dual-degree BA in Biochemistry, Biophysics, and Molecular Biology (BBMB), and Economics with honors from Whitman College, graduating magna cum laude and Phi Beta Kappa —Focus Areas: Health SolutionsLocation: Menlo Park Mr Young is a Managing Director of Longitude Capital Prior to joining Longitude Capital in 2022, Mr Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina for $8 billion in 2021 Prior to joining GRAIL, Mr Young served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals (JAZZ), an LVP1 portfolio company Prior to joining Jazz, Mr Young worked in investment banking for approximately 20 years From February 2009 to April 2013, he served as a Managing Director in global healthcare of Barclays Capital, where he served as co-head of the life sciences group From 2007 to 2008, Mr Young served as a Managing Director of Citigroup, and from 2003 to 2007, as a Managing Director of Lehman Brothers Mr Young holds an MBA and a BS in Economics from the Wharton School of the University of Pennsylvania —Focus Areas: BiotechnologyLocation: Menlo Park Mr Bikoff is a Principal at Longitude Capital Prior to joining Longitude Capital in 2016, Mr Bikoff held a series of strategy, finance, and operating roles at Cardinal Health While at Cardinal Health, he worked to deploy over $6 billion of capital through M&A and minority investments Most recently, Mr Bikoff was the Director of North America Marketing for the Cordis cardiovascular franchise Mr Bikoff currently serves on the board of Polares Medical and is a board observer at Ceribell, Endogenex, Limflow, and Nalu He previously served as a board observer at Amphora (acquired), Eargo (EAR), and RxSight (RXST), and was also actively involved in Longitude Capital’s investment in Axonics Modulation Technologies (AXNX) and PROCEPT BioRobotics (PRCT) Mr Bikoff began his career in Deloitte Consulting’s Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University —Focus Areas: Medical Technology Location: Menlo Park Dr Ely is a Senior Associate at Longitude Capital Prior to joining Longitude Capital full-time in 2022, Dr Ely was a Longitude Research Fellow Dr Ely earned a PhD in Biology from the Massachusetts Institute of Technology, where he specialized in genome engineering and cancer immunology, and a BA in Molecular and Cellular Biology from Vanderbilt University —Focus Areas: Biotechnology Location: Boston Mr Gupta is a Vice President at Longitude Capital Prior to joining Longitude Capital in 2020, Mr Gupta was a Consultant in the MedTech practice at L E K Consulting, where he focused on growth strategy and M&A for corporate and private equity clients in the medical device industry He holds a BS and MS in Biomedical Engineering from the Robert R McCormick School of Engineering and Applied Science at Northwestern University —Focus Areas: Medical TechnologyLocation: Menlo Park Ms Hu is an Associate at Longitude Capital Prior to joining Longitude Capital in 2022, Ms Hu was an Investment Banking Analyst at JP Morgan, where she covered biotechnology and pharmaceutical companies Ms Hu holds a BA in Economics from the University of Chicago —Focus Areas: Biotechnology Location: Boston Manager of Investor Relations & Marketing Ms Jamison is a Manager of Investor Relations and Marketing at Longitude Capital Prior to joining Longitude Capital in 2019, Ms Jamison was an Account Manager at BBDO serving the Allergan and Bayer Crop Science accounts, where she led the development and launch of multi-channel marketing campaigns Ms Jamison holds a BA in Marketing and International Business from the University of Georgia —Focus Areas: Investor Relations & Marketing Location: Menlo Park Dr Kumar is a Vice President at Longitude Capital Prior to joining Longitude Capital in 2022, Dr Kumar was an Engagement Manager at McKinsey & Co where he focused on R&D strategy for biopharmaceutical clients Dr Kumar holds a PhD in Immunology and an MD from Columbia University, and a BA in Economics from Johns Hopkins University —Focus Areas: BiotechnologyLocation: Greenwich Mr Kyon is an Associate at Longitude Capital Prior to joining Longitude Capital in 2022, Mr Kyon was an Investment Banking Analyst at Guggenheim Partners, where he covered medical devices Mr Kyon holds a BS in Business with a concentration in Finance and Statistics from the New York University Leonard N Stern School of Business — Focus Areas: Health Solutions Location: Menlo Park Ms Lai is a Vice President at Longitude Capital Prior to joining Longitude Capital in 2021, Ms Lai was an Investor at HealthQuest Capital, a healthcare venture growth investment firm Prior to HealthQuest Capital, she was a Director at CarePoint Health and worked in the Healthcare Investment Banking Group at Goldman Sachs Ms Lai holds an MBA from Columbia Business School She received her BA in Human Biology from Stanford University — Focus Areas: Health Solutions Location: Menlo Park Ms Li is an Associate at Longitude Capital Prior to joining Longitude Capital in 2021, Ms Li was an Investment Banking Analyst at Lazard, where she covered M&A transactions as part of the Healthcare group Ms Li holds a BA in Biochemistry and Economics from Wellesley College —Focus Areas: BiotechnologyLocation: Greenwich Dr Liu is a Principal at Longitude Capital Prior to joining Longitude Capital in 2018, Dr Liu was an Engagement Manager in the pharmaceuticals and medical products practice of McKinsey & Company Dr Liu is a board observer at Dascena, Endeavor Biomedicines, Quanta Therapeutics, and Vera Therapeutics (VERA) He previously served as a board observer at Inflazome (acquired by Roche) and Talaris Therapeutics (TALS), and was also actively involved in Longitude Capital’s investment in Strongbridge Biopharma (SBBP) Dr Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University —Focus Areas: BiotechnologyLocation: Menlo Park Dr Wang is a Vice President at Longitude Capital Prior to joining Longitude Capital in 2022, Dr Wang was the Senior Director of Strategy & Corporate Development at Dascena, a Longitude portfolio company Prior to Dascena, Dr Wang was an Engagement Manager at L E K Consulting where she consulted life sciences companies on drug development, commercial, and portfolio strategy Dr Wang holds a PhD in Chemical Biology from UC Berkeley, and a BA in Chemical and Physical Biology from Harvard University —Focus Areas: BiotechnologyLocation: Menlo Park Ms Zehfuss is a Research Analyst at Longitude Capital Prior to joining Longitude Capital in 2022, Ms Zehfuss assisted Draper Associates, an early-stage venture capital firm, in identifying potential investment opportunities through the University of Oxford start-up ecosystem Ms Zehfuss holds a Master of Philosophy from the University of Oxford and a BS in Human Biology from Stanford University —Focus Areas: Health SolutionsLocation: Menlo Park Controller - Operations & Tax Ms Cabreros is a Controller – Operations & Tax at Longitude Capital Prior to joining Longitude in 2017, Ms Cabreros was the Tax Controller at Northgate Capital Ms Cabreros started her career with PricewaterhouseCoopers LLP, as a Senior Tax Accountant in the Venture Capital Group, which led to a finance position at ONSET Ventures, an early-stage venture capital investment firm focused on the information and medical technology sectors During her tenure at ONSET, Ms Cabreros was a Senior Accountant, Accounting Manager, and Assistant Controller Ms Cabreros holds a BA in Economics with an emphasis in Accounting from the University of California, Santa Cruz —Location: Menlo Park Compliance and Legal Associate Ms Caruso is a Compliance and Legal Associate at Longitude Capital Prior to joining Longitude Capital in 2022, Ms Caruso was a Compliance Consultant at ACA Compliance Group where she developed and implemented regulatory compliance programs for SEC registered investment advisers Ms Caruso received her JD from the University of San Francisco School of Law and holds a BA in Political Science with a minor in Criminology and Italian — Focus Areas: Legal, ComplianceLocation: Menlo Park Ms Chui is a VP of People at Longitude Capital Prior to joining Longitude Capital in 2022, Ms Chui was a VP, Head of People at Dascena, a Longitude Capital portfolio company Ms Chui holds a BA in Communications, Journalism, and Related Programs from the University of Massachusetts, Amherst — Focus Areas: Human ResourcesLocation: Menlo Park